Temporal expression of transporters and receptors in a rat primary co-culture blood-brain barrier model

Xenobiotica

Volumn 44, Issue 10, 2014, Pages 941-951

  Liu, Houfu ^a   Li, Yang ^a   Lu, Sijie ^a   Wu, Yiwen ^a   Sahi, Jasminder ^a  

^a GLAXOSMITHKLINE   (China)

Author keywords

Brain microvessel endothelial cells; Brain blood barrier; Receptors; Transporters

Indexed keywords

AMANTADINE; AMITRIPTYLINE; AMOXAPINE; AMPRENAVIR; AROMATIC HYDROCARBON RECEPTOR; BREAST CANCER RESISTANCE PROTEIN; BREAST CANCER RESISTANCE PROTEIN 1; CARBAMAZEPINE; CITALOPRAM; CLOZAPINE; CONSTITUTIVE ANDROSTANE RECEPTOR; DANTROLENE; DOXEPIN; FLUPHENAZINE; GABAPENTIN; HALOPERIDOL; INSULIN RECEPTOR; LAMOTRIGINE; LOXAPINE; MAPROTILINE; MESORIDAZINE; MESSENGER RNA; METOCLOPRAMIDE; MIDAZOLAM; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 4; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 1B; PREGNANE X RECEPTOR; RISPERIDONE; SUMATRIPTAN; UNCLASSIFIED DRUG; CARRIER PROTEIN; CELL RECEPTOR; CENTRAL NERVOUS SYSTEM AGENTS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BLOOD BRAIN BARRIER; BRAIN CAPILLARY; BRAIN CAPILLARY ENDOTHELIAL CELL; BRAIN CORTEX; COCULTURE; COMPARATIVE STUDY; DRUG METABOLISM; GENE EXPRESSION; IN VITRO STUDY; KIDNEY; MALE; MDCK CELL LINE; MEMBRANE PERMEABILITY; NONHUMAN; NUCLEOTIDE SEQUENCE; QUANTITATIVE ANALYSIS; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; UPREGULATION; ANIMAL; DOG; ENDOTHELIUM CELL; METABOLISM; SPRAGUE DAWLEY RAT; TIME;

RATTUS;

ANIMALS; ASTROCYTES; BLOOD-BRAIN BARRIER; CENTRAL NERVOUS SYSTEM AGENTS; COCULTURE TECHNIQUES; DOGS; ENDOTHELIAL CELLS; GENE EXPRESSION; MADIN DARBY CANINE KIDNEY CELLS; MALE; MEMBRANE TRANSPORT PROTEINS; MODELS, ANIMAL; RATS, SPRAGUE-DAWLEY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TIME FACTORS;

EID: 84907062398     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2014.919430     Document Type: Article

References (50)

1. Azhar S, Medicherla S, Shen WJ, et al. (2006). LDL and cAMP cooperate to regulate the functional expression of the LRP in rat ovarian granulosa cells. J Lipid Res 47:2538-50.
2. Boado RJ, Pardridge WM. (1994). Measurement of blood-brain barrier GLUT1 glucose transporter and actin mRNA by a quantitative polymerase chain reaction assay. J Neurochem 62:2085-90.
3. Barrand MA, Robertson KJ, von Weikersthal SF. (1995). Comparisons of P-glycoprotein expression in isolated rat brain microvessels and in primary cultures of endothelial cells derived from microvasculature of rat brain, epididymal fat pad and from aorta. FEBS Lett 374:179-83.
4. Campbell SD, Regina KJ, Kharasch ED. (2013). Significance of lipid composition in a blood-brain barrier-mimetic pampa assay. J Biomol Screen 19:437-44.
5. Chow EC, Sun H, Khan AA, et al. (2010). Effects of 1alpha,25-dihydroxyvitamin D3 on transporters and enzymes of the rat intestine and kidney in vivo. Biopharm Drug Dispos 31:91-108.
6. Cucullo L, Aumayr B, Rapp E, Janigro D. (2005). Drug delivery and in vitro models of the blood-brain barrier. Curr Opin Drug Discov Dev 8: 89-99.
7. Dauchy S, Dutheil F, Weaver RJ, et al. (2008). ABC transporters, cytochromes P450 and their main transcription factors: expression at the human blood-brain barrier. J Neurochem 107:1518-28.
8. De Boer AG, Gaillard PJ. (2002). In vitro models of the blood-brain barrier: when to use which? Curr Med Chem Central Nervous System Agents 2:203-9.
9. Demeuse P, Kerkhofs A, Struys-Ponsar C, et al. (2002). Compartmentalized coculture of rat brain endothelial cells and astrocytes: a syngenic model to study the blood-brain barrier. J Neurosci Methods 121:21-31.
10. Di L, Kerns EH, Bezar IF, et al. (2009). Comparison of blood-brain barrier permeability assays: in situ brain perfusion, MDR1-MDCKII and PAMPA-BBB. J Pharm Sci 98:1980-91.
11. Di L, Whitney-Pickett C, Umland JP, et al. (2011). Development of a new permeability assay using low-efflux MDCKII cells. J Pharm Sci 100:4974-85.
12. Donahue JE, Flaherty SL, Johanson CE, et al. (2006). RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease. Acta Neuropathol 112:405-15.
13. Filbrandt CR, Wu Z, Zlokovic B, et al. (2004). Presence and functional activity of the aryl hydrocarbon receptor in isolated murine cerebral vascular endothelial cells and astrocytes. Neurotoxicology 25:605-16.
14. Goh LB, Spears KJ, Yao D, et al. (2002). Endogenous drug transporters in in vitro and in vivo models for the prediction of drug disposition in man. Biochem Pharmacol 64:1569-78.
15. Gutmann H, Török M, Fricker G, et al. (1999). Modulation of multidrug resistance protein expression in porcine brain capillary endothelial cells in vitro. Drug Metab Dispos 27:937-41.
16. Hakkarainen JJ, Jalkanen AJ, Kaariainen TM, et al. (2010). Comparison of in vitro cell models in predicting in vivo brain entry of drugs. Int J Pharm 402:27-36.
17. Hakkarainen JJ, Pajander J, Laitinen R, et al. (2012). Similar molecular descriptors determine the in vitro drug permeability in endothelial and epithelial cells. Int J Pharm 436:426-43.
18. Ishiguro M, Imai Y, Kohsaka S. (1995). Expression and distribution of low density lipoprotein receptor-related protein mRNA in the rat central nervous system. Brain Res Mol Brain Res 33:37-46.
19. Jorgensen L, Van Beek J, Lund S, et al. (2007). Evidence of Oatp and Mdr1 in cryopreserved rat hepatocytes. Eur J Pharm Sci 30:181-9.
20. Kajimoto T, Okada T, Yu H, et al. (2007). Involvement of sphingosine-1-phosphate in glutamate secretion in hippocampal neurons. Mol Cell Biol 27:3429-40.
21. Kotnik K, Popova E, Todiras M, et al. (2009). Inducible transgenic rat model for diabetes mellitus based on shRNA-mediated gene knockdown. PLoS One 4:e5124.
22. Kusuhara H, Sugiyama Y. (2001). Efflux transport systems for drugs at the blood-brain barrier and blood-cerebrospinal fluid barrier (Part 1). Drug Discov Today 6:150-6.
23. Kuteykin-Teplyakov K, Luna-Tortos C, Ambroziak K, Loscher W. (2010). Differences in the expression of endogenous efflux transporters in MDR1-transfected versus wildtype cell lines affect P-glycoprotein mediated drug transport. Br J Pharmacol 160: 1453-63.
24. Lai CH, Kuo KH. (2005). The critical component to establish in vitro BBB model: Pericyte. Brain Res Brain Res Rev 50:258-65.
25. Lundquist S, Renftel M, Brillault J, et al. (2002). Prediction of drug transport through the blood-brain barrier in vivo: a comparison between two in vitro cell models. Pharm Res 19:976-81.
26. Lyck R, Ruderisch N, Moll AG, et al. (2009). Culture-induced changes in blood-brain barrier transcriptome: implications for amino-acid transporters in vivo. J Cereb Blood Flow Metab 29:1491-502.
27. Macias RI, Jimenez S, Serrano MA, et al. (2006). Effect of maternal cholestasis and treatment with ursodeoxycholic acid on the expression of genes involved in the secretion of biliary lipids by the neonatal rat liver. Life Sci 79:1014-19.
28. Miller DS. (2010). Regulation of P-glycoprotein and other ABC drug transporters at the blood-brain barrier. Trends Pharmacol Sci 31: 246-54.
29. Nakagawa S, Deli MA, Kawaguchi H, et al. (2009). A new blood-brain barrier model using primary rat brain endothelial cells, pericytes and astrocytes. Neurochem Int 54:253-63.
30. Perrière N, Demeuse P, Garcia E, et al. (2005). Puromycin-based purification of rat brain capillary endothelial cell cultures. Effect on the expression of blood-brain barrier-specific properties. J Neurochem 93:279-89.
31. Perrière N, Yousif S, Cazaubon S, et al. (2007). A functional in vitro model of rat blood-brain barrier for molecular analysis of efflux transporters. Brain Res 1150:1-13.
32. Polli J, Humphreys J, Wring S, et al. (2000). Comparison of MDCK and bovine brain endothelial cells (BBECs) as a blood-brain barrier screen in early drug discovery. In: Balls M, van Zeller A-M, Halder M, eds. Progress in the reduction, refinement and replacement of animal experimentation (s), New York: Elsevier Science, 271-89.
33. Raggers RJ, Vogels I, van Meer G. (2002). Upregulation of the expression of endogenous Mdr1 P-glycoprotein enhances lipid translocation in MDCK cells transfected with human MRP2. Histochem Cell Biol 117:181-5.
34. Rautio J, Humphreys JE, Webster LO, et al. (2006). In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates. Drug Metab Dispos 34:786-92.
35. Regina A, Koman A, Piciotti M, et al. (1998). Mrp1 multidrug resistance-associated protein and P-glycoprotein expression in rat brain microvessel endothelial cells. J Neurochem 71:705-15.
36. Su T, Waxman DJ. (2004). Impact of dimethyl sulfoxide on expression of nuclear receptors and drug-inducible cytochromes P450 in primary rat hepatocytes. Arch Biochem Biophys 424:226-34.
37. Summerfield SG, Read K, Begley DJ, et al. (2007). Central nervous system drug disposition: the relationship between in situ brain permeability and brain free fraction. J Pharmacol Exp Ther 322: 205-13.
38. Tao-Cheng JH, Nagy Z, Brightman MW. (1987). Tight junctions of brain endothelium in vitro are enhanced by astroglia. J Neurosci 7:3293-9.
39. Tran TT, Mittal A, Gales T, et al. (2004). Exact kinetic analysis of passive transport across a polarized confluent MDCK cell monolayer modeled as a single barrier. J Pharm Sci 93:2108-23.
40. Uchino H, Kanai Y, Kim DK, et al. (2002). Transport of amino acidrelated compounds mediated by L-type amino acid transporter 1 (LAT1): insights into the mechanisms of substrate recognition. Mol Pharmacol 61:729-37.
41. Visser CC, Voorwinden LH, Crommelin DJ, et al. (2004). Characterization and modulation of the transferrin receptor on brain capillary endothelial cells. Pharm Res 21:761-9.
42. Wan H, Rehngren M, Giordanetto F, et al. (2007). High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery. J Med Chem 50: 4606-15.
43. Wang X, Hawkins BT, Miller DS. (2011). Aryl hydrocarbon receptormediated up-regulation of ATP-driven xenobiotic efflux transporters at the blood-brain barrier. FASEB J 25:644-52.
44. Wang X, Sykes DB, Miller DS. (2010). Constitutive androstane receptormediated up-regulation of ATP-driven xenobiotic efflux transporters at the blood-brain barrier. Mol Pharmacol 78:376-83.
45. Wu D, Pardridge WM. (1998). Pharmacokinetics and blood-brain barrier transport of an anti-transferrin receptor monoclonal antibody (OX26) in rats after chronic treatment with the antibody. Drug Metab Dispos 26:937-9.
46. Xia JR, Liu NF, Zhu NX. (2008). Specific siRNA targeting the receptor for advanced glycation end products inhibits experimental hepatic fibrosis in rats. Int J Mol Sci 9:638-61.
47. Yau TM, Li G, Zhang Y, et al. (2005). Vascular endothelial growth factor receptor upregulation in response to cell-based angiogenic gene therapy. Ann Thorac Surg 79:2056-63.
48. Yousif S, Marie-Claire C, Roux F, et al. (2007). Expression of drug transporters at the blood-brain barrier using an optimized isolated rat brain microvessel strategy. Brain Res 1134:1-11.
49. Zhang Y, Li CS, Ye Y, et al. (2006). Porcine brain microvessel endothelial cells as an in vitro model to predict in vivo blood-brain barrier permeability. Drug Metab Dispos 34:1935-43.
50. Zhang AS, Xiong S, Tsukamoto H, Enns CA. (2004). Localization of iron metabolism-related mRNAs in rat liver indicate that HFE is expressed predominantly in hepatocytes. Blood 103: 1509-14.